Back to today’s briefing

Story perspectives

FDA Trial Links Low-Dose CBD to Liver Damage Risks

7/8/2025

34 6

Summary

Story summary

A recent FDA clinical trial with 201 participants uncovered a concerning link between low doses of CBD and elevated liver enzyme levels, suggesting possible liver damage. Although the majority were unaffected, 5% experienced significant spikes, prompting seven withdrawals. These findings underscore the urgent need for awareness about the risks of CBD as its popularity surges across the U.S.

1 of 1

Story summary

A recent FDA clinical trial with 201 participants uncovered a concerning link between low doses of CBD and elevated liver enzyme levels, suggesting possible liver damage. Although the majority were unaffected, 5% experienced significant spikes, prompting seven withdrawals. These findings underscore the urgent need for awareness about the risks of CBD as its popularity surges across the U.S.